Geumhee Gwak

Geumhee Gwak

Auto-generated profile, based on publicly available information

Geumhee Gwak

Department of Surgery, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Seung-Gu YeoSeung-Gu Yeo
Seung-Gu Yeo
JKJuree Kim
Juree Kim
GKGeum-Hee Kwak
Geum-Hee Kwak
JKJi-Young Kim
Ji-Young Kim
KPKyeongmee Park
Kyeongmee Park
SHSehwan Han
Sehwan Han
To investigate the efficacy and safety of accelerated partial breast irradiation (APBI) via high-dose-rate (HDR) multicatheter interstitial brachytherapy for early-stage breast cancer.

21 December 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
JYJin-Sung Yuk
Jin-Sung Yuk
TKTaeran Kim
Taeran Kim
HCHyunjin Cho
Hyunjin Cho
GGGeumhee Gwak
Geumhee Gwak
Although many physicians have been concerned that the menopausal hormones used currently in clinical practice may affect the risk of breast cancer, there are currently few informative updated studies about the associations between menopausal hormone therapy (MHT) and the risk of breast cancer. To evaluate the association between the risk of breast cancer and MHT using the National Health Insurance Database in South Korea (HISK) cohort between 2002 and 2019 retrospectively. Postmenopausal women over 40 years of age from 2003 to 2011 were selected as the subject population and their follow-up data were collected until 2019. We analyzed the risk and mortality of breast cancer according to the type of MHT received, namely, tibolone, combined estrogen plus progestin by manufacturer (CEPM), oral estrogen, combined estrogen plus progestin by physician (CEPP), or topical estrogen. The risk of breast cancer increased in the CEPM group (HR 1.439, 95% CI 1.374–1.507, p-value <0.001) in comparison with the non-MHT group. However, no significant associations were found between the use of tibolone, oral estrogen, CEPP, or topical estrogen and breast cancer risk in comparison with the non-MHT group (HR 0.968, 95% CI 0.925–1.012; HR 1.002, 95% CI 0.929–1.081; HR 0.929, 95% CI 0.75–1.15; HR 1.139, 95% CI 0.809–1.603). The mortality rate from breast cancer is lower in the MHT group in comparison with the non-MHT group, indicating that significant associations were found for tibolone, CEPM and oral estrogen (HR 0.504, 95% CI 0.432-0.588; HR 0.429, 95% CI 0.352-0.522; HR 0.453 95% CI 0.349-0.588, p-value <0.001). This study suggests that the risk of breast cancer is increased by drugs in the CEPM group but not by tibolone, oral estrogen, CEPP, or topical estrogen. The mortality rate from breast cancer is lower with MHT (tibolone, CEPM, oral estrogen) than without MHT.

5 October 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JYJin-Sung Yuk
Jin-Sung Yuk
SYSeung-Woo Yang
Seung-Woo Yang
SYSang-Hee Yoon
Sang-Hee Yoon
MKMyoung Hwan Kim
Myoung Hwan Kim
YSYong-Soo Seo
Yong-Soo Seo
GGGeumhee Gwak
Geumhee Gwak
Both the uterus and breasts have sex hormone dependence, yet there are few studies on the association between breast disease and uterine fibroids (UFs). The purpose of this study was to investigate the incidence of benign breast disease (BBD), carcinoma in situ (CIS), and breast cancer (BC) in women treated for UFs compared to women who were not treated for UFs. This retrospective cohort study used national health insurance data from January 1st, 2011, to December 31st, 2020. We selected women between 20 and 50 years old who (1) were treated for UFs (UF group) or (2) visited medical institutions for personal health screening tests without UFs (control group). We analyzed independent variables such as age, socioeconomic status (SES), region, Charlson comorbidity index (CCI), delivery status, menopausal status, menopausal hormone therapy (MHT), endometriosis, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia based on the first date of uterine myomectomy in the UF group and the first visiting date for health screening in the non-UF group. There were 190,583 and 439,940 participants in the UF and control groups, respectively. Compared with those of the control group, the RRs of BBD, CIS, and BC were increased in the UF group. The hazard ratios (HRs) of BBD, CIS, and BC in the UF group were 1.335 (95% confidence interval (CI) 1.299–1.372), 1.796 (95% CI 1.542–2.092), and 1.3 (95% CI 1.198–1.41), respectively. When we analyzed the risk of BC according to age at inclusion, UFs group had the increased risk of BCs in all age groups in comparison with control group. Women with low SES (HR 0.514, 95% CI 0.36–0.734) and living in rural areas (HR 0.889, 95% CI 0.822–0.962) had a lower risk of BC. Our study showed that women with UFs had a higher risk of BBD, CIS, and BC than those without UFs. This result suggests that women with UFs should be more conscious of BC than those without UFs. Therefore, doctors should consider recommending regular breast self-exams, mammography, or ultrasound for the early detection of BC in women with UFs.

15 March 2020 in Journal of Minimally Invasive Surgery
Verified
Journal Article
Open access
PDF file
BKBomi Kim
Bomi Kim
JKJungbin Kim
Jungbin Kim
IPInseok Park
Inseok Park
HCHyunjin Cho
Hyunjin Cho
GGGeumhee Gwak
Geumhee Gwak
KKKihwan Kim
Kihwan Kim
Bomi Kim, M.D., Jungbin Kim, M.D., Inseok Park, M.D., Hyunjin Cho, M.D., Geumhee Gwak, Ph.D., Keun Ho Yang, Ph.D., Byung-Noe Bae, Ph.D., Kihwan Kim, Ph.D.. Journal of Minimally Invasive Surgery 2020;23:43-8. https://doi.org/10.7602/jmis.2020.23.1.43

1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
TYTae-Kyung Yoo
Tae-Kyung Yoo
YKYoung-Joon Kang
Young-Joon Kang
JJJoon Jeong
Joon Jeong
JSJeong-Yoon Song
Jeong-Yoon Song
SKSun Hee Kang
Sun Hee Kang
BCByung Joo Chae
Byung Joo Chae
Yoo TK, et al. J Breast Cancer. 2021 Dec;24(6):569-577. https://doi.org/10.4048/jbc.2021.24.e51

26 June 2019 in Journal of Breast Disease
Verified
Journal Article
Open access
PDF file
JKJaeyoon Kim
Jaeyoon Kim
YLYujin Lee
Yujin Lee
TYTaeyong Yoo
Taeyong Yoo
JKJungbin Kim
Jungbin Kim
JHJonghee Hyun
Jonghee Hyun
GGGeumhee Gwak
Geumhee Gwak